Becton, Dickinson and Company $BDX Shares Purchased by 44 Wealth Management LLC

44 Wealth Management LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 103.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,355 shares of the medical instruments supplier’s stock after purchasing an additional 5,269 shares during the quarter. 44 Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $1,938,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Creative Planning boosted its stake in Becton, Dickinson and Company by 32.0% during the 3rd quarter. Creative Planning now owns 73,216 shares of the medical instruments supplier’s stock worth $13,704,000 after purchasing an additional 17,753 shares during the last quarter. New England Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 21.4% in the third quarter. New England Asset Management Inc. now owns 36,655 shares of the medical instruments supplier’s stock valued at $6,861,000 after buying an additional 6,465 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 53.8% in the third quarter. AQR Capital Management LLC now owns 1,033,860 shares of the medical instruments supplier’s stock worth $190,623,000 after buying an additional 361,642 shares in the last quarter. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Finally, Credit Agricole S A acquired a new position in Becton, Dickinson and Company during the third quarter worth about $4,290,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2%

Shares of BDX opened at $159.32 on Friday. The company’s 50-day simple moving average is $190.01 and its 200-day simple moving average is $190.01. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market capitalization of $45.36 billion, a PE ratio of 25.99, a P/E/G ratio of 11.55 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the previous year, the business posted $3.43 earnings per share. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.6%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,416 shares of company stock worth $674,693 in the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BDX shares. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Citigroup dropped their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. TD Cowen lifted their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Finally, Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.